In vitro studies indicate that muscarinic cholinergic inhibition of beta-adrenergic cardiac responses may be modulated in part by nitric oxide (NO). To evaluate the role of NO in parasympathetic inhibition of the beta-adrenergic contractile response in vivo, we assessed the inotropic response to dobutamine before and during bilateral vagus nerve stimulation in closed-chest dogs. Dobutamine administration and vagal stimulation were repeated during intracoronary infusion of the NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA, 10 mumol/ min) and again following infusion of L-arginine (100 mg/kg). In eight dogs, intracoronary dobutamine infusion at rates of 25 and 50 micrograms/min increased peak +dP/dt by 131 +/-24 and 168 +/-22%, respectively (P < 0.0001). Vagal stimulation (2.5 Hz) attenuated the responses to dobutamine (25 and 50 micrograms/min) by 23 +/-4 and 21 +/-4%, respectively (P < 0.001). L-NMMA reduced (by 44-62%; P < 0.001) and L-arginine restored vagal inhibition ... 
Introduction
In vitro studies indicate that muscarinic cholinergic inhibition of 18-adrenergic cardiac responses may be modulated in part by nitric oxide (NO). To evaluate the role of NO in parasympathetic inhibition of the J8-adrenergic contractile response in vivo, we assessed the inotropic response to dobutamine before and during bilateral vagus nerve stimulation in closed-chest dogs. Dobutamine administration and vagal stimulation were repeated during intracoronary infusion of the NO synthase inhibitor NG-monomethyl-L-arginine (L-NMMA, 10 gmol/min) and again following infusion of L-arginine (100 mg/kg). In eight dogs, intracoronary dobutamine infusion at rates of 25 and 50 gg/min increased peak +dP/dt by 131+24 and 168±22%, respectively (P < 0.0001). Vagal stimulation (2.5 Hz) attenuated the responses to dobutamine (25 and 50 ,Lg/min) by 23±4 and 21+4%, respectively (P < 0.001). L-NMMA reduced (by 44-62%; P < 0.001) and L-arginine restored vagal inhibition of the dobutamine-stimulated inotropic response. In a second group of nine dogs, dobutamine was administered systemically to assure a constant concentration in the coronary circulation. Vagal stimulation (2.5 Hz) attenuated the dobutamine-stimulated inotropic response (2.5 and 5.0 ,ug/ kg per min) by 40+12% and 57±8%, respectively (P < 0.004). As with intracoronary dobutamine, L-NMMA diminished and L-arginine restored vagal inhibition of the inotropic response to dobutamine. Intracoronary infusion of atropine (12 ,ug/min) abolished the vagal inhibitory effect, and intracoronary infusion of 8-bromo-cyclic GMP (1 and 10 mM) caused a dose-dependent attenuation of the dobutamine-stimulated increase in +dP/dt. These data suggest that NO mediates, at least in part, vagal inhibition of the inotropic response to /8-adrenergic stimulation by dobutamine, and thus may play a role in normal physiologic regulation of myocardial autonomic responses. (J. Clin. Invest. 1995 The sympathetic and parasympathetic limbs of the autonomic nervous system play important and countervailing roles in regulating heart rate, atrioventricular conduction, and myocardial contractility. Sympathetic stimulation increases heart rate, conduction, and contractility, whereas parasympathetic stimulation slows both sinus node rate and atrioventricular conduction (1) (2) (3) (4) (5) (6) . Although it has little effect on ventricular contractility under basal conditions, an increase in vagal nerve activity attenuates the contractile response to sympathetic stimulation (1, 4) and infused 6-adrenergic agonists (2, 3, 5, 6) . Likewise, the intracoronary infusion of acetylcholine attenuates the inotropic response to sympathetic nerve stimulation (5) and infused f3-adrenergic agonists (5, 6) .
There is evidence to suggest that nitric oxide (NO)' may influence the autonomic regulation of cardiac function. In isolated myocytes, NO has been shown to play a role in both muscarinic-cholinergic slowing of heart rate and attenuation of the contractile response to /3-adrenergic stimulation (7) . NO acts by stimulating soluble guanylyl cyclase (8) (9) (10) to produce cyclic GMP (cGMP). In the heart, muscarinic-cholinergic stimulation also leads to increased cGMP production (11) (12) (13) (14) (15) which, in turn, may counteract the contractile effects of cAMP (16, 17) . Thus, there is theoretical support for the thesis that NO plays a role in modulating the interaction between the adrenergic and cholinergic arms of the autonomic nervous system.
Despite the well-characterized role of NO in modulating myocyte function in vitro, the role of NO in modulating myocardial contractility in vivo remains undefined. NO is involved in vagally mediated pulmonary (18) and coronary vasodilation (19) , and in nonadrenergic, noncholinergic neurotransmission in animals (20, 21) and humans (22, 23 Experimental protocols Intracoronary dobutamine. Animals were allowed to stabilize for 30 min after instrumentation. After stabilization, intracoronary drug infusions were administered via a specifically designed 6-French catheter (Interventional Medical, Danvers, MA), positioned at the ostium of the left main coronary artery via the right femoral artery. Catheter placement was documented fluoroscopically before each intracoronary drug infusion. Dobutamine (Eli Lilly and Co., Indianapolis, IN) was infused into the coronary artery for S min at rates of 25 and 50 M.g/min. Hemodynamic responses were assessed at a constant paced heart rate. The right atrium was paced at a rate of 170 to 180 beats per min (bpm) (-10 bpm above the rate achieved with the highest dose of dobutamine) using an external pacemaker (model 3070; Siemens Pacesetter, Sylmar, CA). Dual chamber pacing (atrioventricular interval 150 ms) was used in two dogs in which vagal stimulation inhibited atrioventricular conduction. All hemodynamic measurements were performed at end-expiration and mean values were determined from the average of 10 consecutive cardiac cycles. After steady-state measurements, bilateral vagal nerve stimulation (15 V, 0.5 ms) was applied at 2.5 and 5.0 Hz in random order for 90 s. Vagal nerve stimulation caused drops in mean BP of 15 mmHg. The intraaortic balloon was inflated in a graded fashion with an inflation device (model SM 2500; SciMed, Maple Grove, MN) to maintain BP within 10 mmHg at a given dobutamine dose with and without vagal stimulation. Inhibition of NOS was achieved by intracoronary infusion of NG-monomethyl-L-arginine (L-NMMA; CalbiochemNovabiochem Corp., La Jolla, CA) at a rate of 10 ,umol/min which yields a coronary concentration of 100 MM, assuming a total left coronary flow of 100 ml/min (19) . After a 20-min infusion of L-NMMA and during concurrent administration of L-NMMA, vagal nerve stimulation was repeated without and with intracoronary infusion of dobutamine.
Intravenous dobutamine. Because L-NMMA attenuates both cholinergic ( 19) and ,/-adrenergic (24) vasodilator effects, the final coronary artery concentration of dobutamine infused via the coronary artery could potentially be higher during concurrent L-NMMA infusion. To assure delivery of a constant concentration of dobutamine to the myocardium, independent of coronary flow rates, in a second group of nine dogs, dobutamine was administered via a peripheral vein at rates of 2.5 and 5.0 Mg/kg per min. As with the intracoronary protocol, these experiments were performed at a paced heart rate (dual chamber, atrioventricular sequential pacing) and with graded inflations of a balloon in the descending aorta to maintain arterial pressure constant to within 10 mmHg during vagal nerve stimulation. L-NMMA was administered by intracoronary infusion (10 [mol/min for 20 min).
Reversal of NOS inhibition with L-arginine
To test the specificity of L-NMMA as an inhibitor of NOS, L-arginine (100 mg/kg; Sigma Chemical Co.), the substrate for NOS (25) , was administered as a peripheral bolus after L-NMMA infusion, and the effect of vagal nerve stimulation retested. The effect of L-arginine was tested in six of the dogs receiving intracoronary dobutamine and in all nine animals receiving intravenous dobutamine.
The role of the muscarinic receptor 
Hemodynamic measurements
The peak rate of rise of left ventricular pressure (+dP/dt) was used to assess contractility (26) . The intracoronary infusion of drugs largely eliminates peripheral vascular effects (27) that might alter loading conditions and affect the utility of +dP/dt as a contractile index. In addition, heart rate was held constant by pacing and an intraaortic balloon was inflated to maintain arterial pressure constant within 10 mmHg during vagal stimulation.
Dobutamine caused a small increase in BP. Because of this, a second measure of contractility, the maximal velocity of contractile element shortening, VPM, was also derived (26) . This index, which is relatively afterload insensitive, is calculated as: 
Data analysis
Data are presented as meantSEM. Concentration-effect relationships for dobutamine in the presence and absence of L-NMMA or vagal nerve stimulation were compared using ANOVA with repeated measures (28) . The effects of L-NMMA and L-arginine on the responses to vagal stimulation were assessed with three-way ANOVA using as terms (a) the dobutamine dose, (b) the presence or absence of L-NMMA, and (c) an identification term to match individual dog data. To determine whether the L-NMMA or L-arginine treatment effects depended on dobutamine dose, a factorial design ANOVA analysis was performed to test the statistical significance of an interaction term (treatment dose X dobutamine) (28) . A significant interaction term indicates that the treatment effect depends on the dobutamine dose, and post hoc testing is required Nitric Oxide and Myocardial Contractility Animals were prepared as described in Methods. Heart rate was maintained constant by pacing at 10 bpm above the maximum heart rate achieved with dobutamine. Results represent mean+SEM from eight animals. VPM = (+dP/dtmaD,)/PdeV. * P < 0.0005; 1 P < 0.0002; and § P < 0.0001 for dobutamine effect (ANOVA with repeated measures).
(28). Conversely, an insignificant interaction term is evidence that the treatment effect was unaltered by the dobutamine dose. Statistical analyses were performed both for absolute measurements, and in some cases, for percentage change from baseline. The effects of vagal stimulation during atropine infusions were similarly analyzed by three-way ANOVA. Post hoc, univariate t tests with the Bonferonni correction were used to assess the statistical significance of changes in +dP/dt induced by vagal stimulation. Changes were considered significant if the null hypothesis was rejected at a level of P < 0.05.
Results
Effect of vagal nerve stimulation on the positive inotropic response to intracoronary dobutamine. Before infusion of intracoronary dobutamine, baseline +dP/dt was 2,445±181 mmHg/ s (Table I) (Table  I ), but significantly reduced the ability of vagal nerve stimulation (2.5 Hz) to inhibit the contractile response to dobutamine by 62±8 and 44±15% at dobutamine infusion rates of 25 and 50 ,g/min, respectively (P < 0.001 by three-way ANOVA; Fig. 2 ). Factorial analysis revealed an insignificant interaction term (F = 0.06, P = 0.95) indicating a similar effect of L-NMMA at all infusion rates of dobutamine. L-NMMA attenuated, to a similar degree, the vagal inhibitory effect at 5.0 Hz (data not shown).
Role ofloading conditions and heart rate. The intracoronary infusion of L-NMMA had no effect on mean arterial pressure, left ventricular end-diastolic pressure, or coronary perfusion pressure (Table II) . Both mean arterial pressure (P < 0.0002 by ANOVA) and coronary perfusion pressure (P < 0.0001 by ANOVA) increased with infusion of dobutamine; however, neither was affected by L-NMMA administration. Decreases in blood pressure with vagal nerve stimulation were circumvented by graded inflation of an intraaortic balloon to maintain blood pressure within 10 mmHg of the baseline value.
To exclude further potential confounding effects of changes in arterial pressure on +dP/dt, a second, relatively load-insensitive index of contractility, VPM (26) , was also calculated (Table  I) 160±9t Animals were prepared as described in Methods. Heart rate was maintained constant by pacing at 10 bpm above the maximum heart rate achieved with dobutamine. Results represent mean±SEM from nine animals. HR, heart rate; MAP, mean arterial pressure; LVEDP, left ventricular enddiastolic pressure; CPP, coronary perfusion pressure. * P < 0.0002 and I P < 0.0001 for dobutamine effect (three-way ANOVA).
nize the dobutamine-stimulated VPM response by 34+23% and 62+10% (P < 0.04 for L-NMMA effect by three-way ANOVA) at dobutamine infusion rates of 25 and 50 Mg/min,
respectively. An insignificant interaction term (F = 0.22, P = 0.8) indicated that this effect was similar at both dobutamine infusion rates. Thus, the effect of L-NMMA, as assessed by VPM, was qualitatively and quantitatively similar to that seen with +dP/dt. Peripheral dobutamine infusion. Since NOS inhibition may inhibit the coronary vasodilator effects of vagal and/or /3-adrenergic stimulation, coronary blood flow could potentially be reduced during L-NMMA infusions. If this were the case, the relative dobutamine concentrations achieved with intracoronary infusions would be increased by L-NMMA. To address this possibility, in nine dogs dobutamine was administered intravenously to assure a constant concentration in the coronary circulation, independent of any change in coronary blood flow.
Before the administration of peripheral dobutamine, baseline +dP/dt was 2,667+199 mmHg/s. The response to vagal nerve stimulation in the presence and absence of peripheral dobutamine is depicted in Fig. 3 . In the absence of dobutamine, vagal nerve stimulation decreased +dP/dt by 181±+79 (P = ns) and 195±+134 mmHg (P = ns) at 2.5 and 5.0 Hz, respectively. Peripheral dobutamine infusion at rates of 2.5 and 5.0 ,ug/kg per min increased +dP/dt by 2,319±348 and 3,250+495 mmHg, respectively (P < 0.0001 by ANOVA with repeated measures). Vagal nerve stimulation at 2.5 Hz inhibited the contractile responses to dobutamine by 40±12 and 57+±8% (P < 0.004 by ANOVA with repeated measures) at infusion rates of 2.5 and As with intracoronary dobutamine infusion, L-NMMA did not affect the contractile response to peripheral dobutamine (data not shown), but significantly attenuated vagal inhibition of the dobutamine-stimulated increase in peak +dP/dt (Table  III and Fig. 4 ). The effect of L-NMMA was not dependent on the infusion rate of dobutamine. As with the intracoronary infusion protocol, mean arterial pressure and coronary perfusion pressure were not affected by intracoronary L-NMMA (Table IV) .
Reversal of L-NMMA with L-arginine. To confirm that the effect of L-NMMA was specific for inhibition of NOS, L-arginine was infused via a peripheral vein (bolus, 100 mg/kg) immediately after the infusion of L-NMMA. As depicted in Table III and Fig. 4 , L-arginine restored the inhibitory effect of vagal nerve stimulation toward control values (P < 0.01 vs L-NMMA and P = NS vs baseline). L-arginine had a similar effect during intracoronary dobutamine infusion (n = 6, data not shown).
Effects of muscarinic receptor blockade and exogenous cGMP. Vagal-stimulated NO activity in the heart could occur in Table III 
Discussion
This study tested the hypothesis that NO is involved in the autonomic regulation of myocardial contractility in normal dogs. Using both intracoronary and intravenous dobutamine as a ,3-adrenergic stimulus, and the direct stimulation of the cervical vagus nerves to increase cardiac parasympathetic tone, we reproduced the well-described antagonistic interaction between the parasympathetic and sympathetic limbs of the autonomic nervous system ( 1-6). The role of NO was tested by inhibiting NOS with the concurrent intracoronary infusion of L-NMMA. Under the conditions of this study, L-NMMA significantly reduced by the inhibitory effect of vagal nerve stimulation by -60%. We further demonstrated that the vagal inhibitory effect can be restored by L-arginine, eliminated by atropine, and mimicked by 8-bromo-cGMP.
Several lines of evidence now support a role for NO in the physiologic regulation of the heart. Shulz et al. (29) demonstrated NOS activity in rat ventricular tissue by measuring the formation of L-citrulline, which is produced in the conversion of L-arginine to NO (25) . In cultured myocytes, Balligand et al. (7) have demonstrated that cholinergic agonists stimulated NO production and that inhibition of NOS attenuated the slowing of myocyte beating rate by cholinergic agonists. These findings suggest that NO modulates parasympathetic effects on heart rate (7).
There is controversy as to whether NO influences basal myocardial contractility. Balligand et al. (7) found that NOS inhibition did not affect basal contractility, but augmented the contractile response to /3-adrenergic stimulation. In contrast, Brady et al. demonstrated that NO, as delivered by nitroprusside or as NO gas in solution, exerted a negative inotropic effect in cultured guinea pig myocytes (30) . Data from other studies in isolated myocytes (7) and humans (31) have not confirmed these observations. In the present study, we did not observe an effect of L-NMMA on basal +dP/dt. Thus, the influence of NO on contractility may be more apparent in the presence of /3-adrenergic stimulation.
We explored the mechanism by which L-NMMA attenuated vagal inhibition of the contractile response to dobutamine. Larginine, the substrate for NOS (25) , restored the ability of vagal stimulation to attenuate the dobutamine response. This finding supports the conclusion that the observed effect of L-NMMA is mediated via inhibition of NOS. Certain arginine analogues, notably the alkyl esters, act as muscarinic receptor inhibitors (32) . However, L-NMMA, the NOS inhibitor used in this study has been demonstrated not to inhibit the muscarinic receptor (32) . It should be noted that the intracoronary L-NMMA concentration of 100 yM achieved in this study may not inhibit NOS fully (33, 34) , and thus may underestimate the role of NO.
Secondly, to assess whether the vagal inhibitory effect depended on an intact muscarinic receptor, the contractile effects of vagal nerve stimulation on dobutamine were assessed in atropine-treated dogs. The complete elimination of the vagal inhibitory effect by atropine indicates that vagal-stimulated NO activity occurs in series with stimulation of the muscarinic re- Second, loading conditions can affect +dP/dt. Although loading conditions were not affected by L-NMMA, dobutamine produced a small increase in systemic blood pressure. To control for this effect, VPM, the maximal velocity of contractile element shortening, a relatively load-independent index of contractility, was also examined (26) . Using this index, the effect of vagal stimulation and the attenuation of this effect by NOS inhibition were qualitatively and quantitatively similar to the effects observed with peak +dP/dt. Therefore, it is unlikely that our observations are dependent on the minor changes in blood pressure that occurred.
Previous studies have provided evidence that muscarinic receptor stimulation stimulates NO activity. Cholinergic stimulation has been shown to increases myocardial cGMP (11) . Furthermore, nonhydrolyzable analogues of cGMP, such as dibutyryl cGMP or 8-bromo-cGMP, inhibit both the rate (35) and amplitude (36, 37) of myocyte contraction in vitro, thus mimicking the effects of cholinergic agonists. Of note, the negative inotropic effect of acetylcholine correlates with the increase in myocardial cGMP (12) in the isolated perfused rat heart. Thus, it is reasonable to suggest that vagal stimulation exerts a negative inotropic effect, at least in part, via an NO-mediated increase in cGMP.
Traditionally, muscarinic effects on contractility have been ascribed to activation of an inhibitory G protein that reduces the production of cAMP by adenylyl cyclase (15) . Reductions in cAMP levels in response to muscarinic stimulation, however, have not been consistently demonstrated ( 14) . Our data suggest that a second, NO-dependent, and presumably cGMP-mediated, mechanism may also be involved. There are several possible mechanisms by which cGMP might attenuate myocyte contractility. cGMP may inhibit the L-type slow inward Ca2" current in myocardium by either the stimulation of a cGMP-dependent cAMP phosphodiesterase (16) and/or via a cGMP protein kinase (17) . More recently, NO donors have been shown to inhibit /3-adrenergic-stimulated rises in inward Ca2" current in frog myocytes (38) and rabbit sinoatrial cells (39) . Han While this and other studies strongly suggest that NO has a physiologic function in the heart, its cell(s) of origin has not been determined. Several potential sources of NO exist in the heart. Cardiac myocytes, per se, appear capable of NO synthesis (7, 40 ). Endothelial cells represent another possible source of cardiac NO (19) , including constitutive production by largevessel endothelium and inducible production by cardiac microvascular endothelium (41 (43) . Similarly, Brady et al., using isolated adult guinea pig myocytes, showed that NOS inhibition restored the reduced contractile amplitude of myocytes from endotoxin-treated animals (44) . Cytokines may increase myocardial NO production by the stimulation of an inducible isoform of NOS (29, 40, 41) .
In summary, these observations show, for the first time in vivo, that NO is involved in the parasympathetic regulation of myocardial contractility. We have previously shown that muscarinic-cholinergic stimulation of the human heart, via the intracoronary infusion of acetylcholine, inhibits the positive inotropic response to /3-adrenergic stimulation (6) . The present findings, therefore, have implications for normal human physiology and may be relevant to pathophysiologic states associated with increased NO production.
